Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II trial of Herceptin (NSC 688097) [trastuzumab] and weekly docetaxel (NSC 628503) in androgen-independent (hormone refractory) adenocarcinoma of the prostate (CaP).

Trial Profile

Randomized phase II trial of Herceptin (NSC 688097) [trastuzumab] and weekly docetaxel (NSC 628503) in androgen-independent (hormone refractory) adenocarcinoma of the prostate (CaP).

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Trastuzumab (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Jan 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 22 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top